Form: CORRESP

A correspondence can be sent as a document with another submission type or can be sent as a separate submission.

November 7, 2017

 

 

 

November 7, 2017

 

Division of Corporation Finance

Office of Healthcare & Insurance

Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

Attention: Dorrie Hale and Suzanne Hayes  

 

Re: Responses to the Securities and Exchange Commission
Staff Comments dated November 6, 2017, regarding
AntriaBio, Inc.
Amendment No. 1 to Registration Statement on Form S-1
Filed October 31, 2017
File No. 333-220585

 

Dear Ms. Yale and Ms. Hayes:

 

This letter responds to the staff’s comments set forth in the November 6, 2017 letter regarding the above-referenced Amendment No. 1 to Registration Statement on Form S-1 (the “Registration Statement”). For your convenience, the Staff’s comments are included below and we have numbered our responses accordingly.

 

In some of the responses, we have agreed to change or supplement the disclosures in future filings. We are doing so in the spirit of cooperation with the staff of the Securities and Exchange Commission, and not because we believe our prior filing is materially deficient or inaccurate. Accordingly, any changes implemented in future filings should not be taken as an admission that prior disclosures were in any way deficient. We have also indicated in some responses that we believe no change in disclosure is appropriate, and have explained why. Our responses are as follows:

 

Amendment No. 1 to Registration Statement on Form S-1

 

Documents Incorporated by Reference, page 30

 

Staff Comment No. 1.

 

Please revise your incorporation by reference section to incorporate the Form 8-K filed on November 3, 2017.

 

AntriaBio, Inc.’s Response:

 

We have updated the “Documents Incorporated by Reference” section in the Amendment to incorporate the 8-Ks we’ve subsequently filed.

 

 

 

 

Division of Corporation Finance

Office of Healthcare & Insurance

Securities and Exchange Commission
November 7, 2017

Page 2

 

* * * * *

 

AntriaBio, Inc. hereby acknowledges that:

 

· AntriaBio, Inc. is responsible for the adequacy and accuracy of the disclosure in the filing.

 

· Staff comments or changes to disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to the filing.

 

· AntriaBio, Inc. may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

 

Thank you for your review of the filing. If you should have any questions regarding the response letter, please do not hesitate to contact the undersigned at 303-222-2128, or Anthony Epps of Dorsey & Whitney LLP at (303) 352-1109.

 

  Sincerely,
  AntriaBio, Inc.
   
  /s/ Nevan Elam
   
  Nevan Elam
  Chief Executive Officer

 

cc: Anthony Epps, Dorsey & Whitney LLP

Michael Weiner, Dorsey & Whitney LLP